XOMA
2910 Seventh Street
Berkeley
California
94710
United States
Tel: (510)-204-7200
Website: http://www.xoma.com/
Email: BizDevInfo@xoma.com
24 articles with XOMA
-
Agenus Closes $15 Million Partial Royalty Monetization With XOMA
9/21/2018
Agenus Inc. cancer vaccines, and adoptive cell therapies1, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation
-
The company burned through $1.2B and never brought a drug to market in its 37 years.
-
3 Biopharmas Worth Watching in 2018
1/15/2018
Here are three biopharma stocks worth keeping an eye on. -
XOMA Strengthens Leadership Team With Appointments of Chief Business Officer and General Counsel
1/8/2018
Dr. Datta and Mr. Hart will report to XOMA’s Chief Executive Officer, Jim Neal.
-
Top 6 Biotech Stocks of 2017
12/20/2017
When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates. -
Top 3 Biotech Stocks That Rocked in 2017
12/18/2017
Biotech stocks rocked in 2017, at least a lot of them did. -
Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities under the license.
-
XOMA Reports Third Quarter 2017 Financial Results
11/7/2017
XOMA made important progress positioning the Company for long-term strategic success.
-
XOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries
10/4/2017
-
XOMA Presents Positive Data From PTH1R Monoclonal Antibody Program
4/18/2017
-
XOMA Corporation To Present At The Piper Jaffray Healthcare Conference
11/24/2014
-
Berkeley's XOMA Corporation To Stop Testing Drug As Arthritis Treatment, Shares Plunge
3/6/2014
-
XOMA Corporation’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity In Phase 2B Study Of Treatment-Naïve Adults
3/5/2014
-
Domain Therapeutics Enters Into Collaboration With XOMA Corporation
2/4/2014
-
XOMA Corporation Announces Clinical Study Investigating Gevokizumab in Patients With Non-Infectious Anterior Scleritis Has Opened for Enrollment at the National Eye Institute
4/10/2013
-
XOMA Corporation Announces Servier Has Initiated a Proof-of-Concept Gevokizumab Study in Patients With a History of Acute Coronary Syndrome
11/29/2012
-
XOMA Corporation's Nails Hypertension Trial, Seeks to Sublicense Drug
11/23/2012
-
XOMA Corporation Lands Orphan Drug Status for Eye Disease Treatment
8/24/2012
-
Oncobiologics Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMA's Fully Human Antibody Libraries for Their Discovery Platform
7/31/2012
-
CMC Biologics Acquires XOMA Corporation's Bay Area Manufacturing Facility
7/31/2012